Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that HER2-negative and PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.